Vivek Subbiah: Using ePROs to prompt direct patient trial invitations

Vivek Subbiah shared a post on X:

“Published in JAMA Oncology.
Using ePROs to prompt direct patient trial invitations resulted in greater enrollment to a symptom-intervention trial than standard of care physician-based referral.”

Read further.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.